ERBB2 and breast cancer: For example, integration of HER2 targeted monoclonal antibodies, antibody‐drug conjugates, and cytotoxic drugs has significantly improved prognosis for patients with HER2+ breast cancer regardless of initial tumor size and lymph node involvement.9